Abstract
Here in this abstract we retrospectively review preliminary findings on 374 samples of circulating DNAextracted from 173 patients treated by multitargeted epigenetic therapy (MTET), which is a combination of natural histone deacetylase inhibitors and DNMT methyl transferase inhibitors. This therapy could dynamically interrupt the expression of altered genes, in a variety of solid tumor types, both in invitro and invivo models. We hypothesize that serial monitoring of the circulating DNA provides a feasible option for therapeutic decisions making based on presence of the driver genes in these cases. We also were able to track the antineoplastic response in these group of patients by monitoring their tumor circulating DNA mutated allele fractions and propose a direct correlation with interim epigenetic therapy effectiveness.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Clinical Case Studies Reviews & Reports
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
